News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Introgen Therapeutics, Inc. (INGN) and Gendux Submit First Marketing Authorization Application for ADVEXIN



11/13/2007 10:31:19 AM

DUBLIN, Ireland & AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) and its subsidiary, Gendux Molecular Limited (“GML”), today announced that a Marketing Authorization Application (MAA) has been submitted to the European Medicines Agency (EMEA) for ADVEXIN®, a targeted p53 tumor suppressor therapy for the treatment of Li-Fraumeni Syndrome cancers (LFS).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES